First half-year results for FY 2013

(period ended 31 December 2012)

Supplemental Information for Prima BioMed Conference Call
on March 7, 2013

ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034

PRIMA BIOMED

Important Notice

The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please contact Prima BioMed and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

PRIMA BIOMED

CVac Overview

Manufacturing of CVac



MNCs (white blood cells) taken from the patient by apheresis and sent to lab

MNCs separated and matured to decdritic cells (DCs) with growth factors

DCs are pulsed with the antigen Mannan-Mucin-1 Fusion Protein (MFP)

Mucin-1-antigen is internalized by the DCs

The DCs washed, formulated, and frozen as 1ml vials

Mechanism after injection



Mucin-1 is overexpressed on ovarian cancer cells

Cvac administered as 4 intradermal injections at each dose

CVac activates CD8+ T-cells specific to mucin 1

T cells target mucin 1 overexpressed on cancer cells

T cells kill cancer cells

PRIMA BIOMED

Company strategy

- Developing personalized immunocellular therapeutics for cancer
- Establishment of a robust global supply, logistics, and manufacturing platform leads to clinical and commercial success
- Video review of Prima's manufacturing is available at http://primabiomed.com.au/movies/movie_5.php
- Goals: monetize our assets through commercial product partnerships or licenses; increase value through continued investment in our operational platform and deepen our product pipeline

PRIMA BIOMED

Manufacturing development

- Scaled up manufacturing of the mucin antigen (M-FP)
- Achieved comparability of product manufacturing in three global facilities (Australia, USA, Germany); demonstrates our capability to transfer the technology into new facilities and it paves the way for future scale up into larger facilities when needed
- Implemented automated logistics management software – coordinates manufacturing facilities, dozens of cell collections centers, hundreds of hospitals, the couriers, our laboratories, and Prima's quality managers around the globe
- Customized and validated shipping materials for CVac to allow for greater flexibility in the shipping timelines for CVac
- Inspected and approved 45 cell collection centers that will be able to collect blood product for making CVac across 13 countries; plan for 52 cell collection centers in 15 countries integrated into our quality system through CY 2013
- Planning for careful scale up of production capacity from 63-patient trial to nearly 1000-patient trial

PRIMA BIOMED

Clinical development – ovarian cancer

- Focus of Prima's development has been on newly diagnosed, stage III/IV, epithelial ovarian cancer patients who achieve remission after standard first-line debulking surgery and platinum/taxane chemotherapy
- Significant unmet medical need and low levels of potential competition
- EOC is receptive to immunotherapy approaches
- Targeting patients with low tumor burden reasonably intact immune system

PRIMA BIOMED

Clinical trials – ovarian cancer

- CAN-003: positive interim data reported in October & November 2012:
  - Trend of improved PFS in CVac patients
  - CVac induces a mucin 1 specific t cell response
- CAN-003: upcoming data for all 63 patients:
  - Final immune monitoring data in 3rd quarter of CY 2013
  - Final PFS and initial OS data in 4th quarter of CY 2013
- CAN-004 (CANVAS): status update:
  - Underway in 4 countries and 26 clinical sites
  - Controlled rollout through 2013

PRIMA BIOMED

Financial results for the Half-Year ended 31 December 2012*

Loss after tax: A$ 8,030,406
Loss per basic and diluted share: 0.75 cents (A$ 0.0075 per share)

<u>Loss is down 13.78% to corresponding period last year:</u>
Loss after tax: A$ 9,314,047
Loss per basic and diluted share: 0.92 cents (A$ 0.0092 per share)

G&A expenses: appx A$ 2.6 million (down from A$ 3.3 million)

R&D expenses: appx A$ 7.3 million (down from A$ 7.5 million)

Cash & term deposits: appx A$ 28 million
(does not include A$ 1.4 million accrued during the reporting period but received after the reporting period in February 2013)

*according to International Financial Reporting Standards (IFRS).
Results to be read in conjunction with notes from the Company's Half-Year Report and previous year's Annual Report, both published in compliance with ASX listing rule 4.2A.

PRIMA BIOMED

Income statement for the Half-Year ended 31 December 2012*

(unaudited)	31 December 2012	31 December 2011
	A$	A$
OTHER INCOME		
Total other income	2,079,220	3,031,479
EXPENSES		
Depreciation and amortisation	(118,138)	(78,922)
Research and development and intellectual property	(7,279,338)	(7,515,131)
Corporate administrative expenses	(2,607,964)	(3,281,424)
Changes in fair value of derivative financial instruments	(37,190)	(1,470,049)
Loss before income tax	(7,963,410)	(9,314,047)
Income tax expense	(66,996)	-
Loss for the half-year	(8,030,406)	(9,314,047)

*according to International Financial Reporting Standards (IFRS).
Results to be read in conjunction with notes from the Company's Half-Year Report and previous year's Annual Report, both published in compliance with ASX listing rule 4.2A.

PRIMA BIOMED

Exciting year ahead

- Continued scale up of manufacturing and expanding our cell collection network
- Phase 2 results in ovarian cancer trial:
  - 3Q CY13 – immune monitoring profile
  - Q4 CY13 – PFS and OS data
- Continued rollout of CANVAS
- CVac opportunities for other cancer targets in phase 2 / POC trials

PRIMA BIOMED